---
title: "Huaren Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 37.3329 million yuan, a year-on-year decrease of 49.01%"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/253206678.md"
description: "Huaren Pharmaceutical released its semi-annual report for 2025, with operating revenue of 624 million yuan, a year-on-year decrease of 19.13%; net profit attributable to the parent company of 37.3329 million yuan, a year-on-year decrease of 49.01%; net profit excluding non-recurring gains and losses of 27.6892 million yuan, a year-on-year decrease of 59.17%; basic earnings per share of 0.0316 yuan"
datetime: "2025-08-15T11:33:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253206678.md)
  - [en](https://longbridge.com/en/news/253206678.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253206678.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/253206678.md) | [English](https://longbridge.com/en/news/253206678.md)


# Huaren Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 37.3329 million yuan, a year-on-year decrease of 49.01%

According to the Zhitong Finance APP, Huaren Pharmaceutical (300110.SZ) released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 624 million yuan, a year-on-year decrease of 19.13%. The net profit attributable to shareholders of the listed company was 37.3329 million yuan, a year-on-year decrease of 49.01%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 27.6892 million yuan, a year-on-year decrease of 59.17%. The basic earnings per share were 0.0316 yuan

### 相關股票

- [Huaren Pharmaceutical (300110.CN)](https://longbridge.com/zh-HK/quote/300110.CN.md)

## 相關資訊與研究

- [Huaming Files For Hong Kong IPO, Riding Power Equipment Boom](https://longbridge.com/zh-HK/news/279427411.md)
- [Shanghai Pharmaceuticals Passes Generic Drug Evaluation for Antibiotic](https://longbridge.com/zh-HK/news/279536547.md)
- [New Buy Rating for Kingboard Laminates Holdings (1888), the Technology Giant](https://longbridge.com/zh-HK/news/279535649.md)
- [08:24 ETZentiva vydává Zprávu o udržitelnosti za rok 2025, čímž posiluje svůj závazek vůči lidem, partnerům a planetě.](https://longbridge.com/zh-HK/news/279431011.md)
- [CStone to Showcase Three ADC Pipeline Programs at 2026 AACR Meeting](https://longbridge.com/zh-HK/news/279530416.md)